CFLAR and hepatocellular carcinoma: Coordinating the up-regulation of death receptors and downregulation of cFLIP and Bcl-2 family members by HDACi (Figure 11a) has also been described to a variable extent in leukemia ([66,118,120,121,203,204], breast carcinoma [199,205], lung carcinoma [119,178,199], glioblastoma [197,206], neuroblastoma [168,207], hepatocellular carcinoma [208,209], or bladder carcinoma [119,210,211].